Hedeker Wealth LLC Increases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Hedeker Wealth LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,534 shares of the medical research company’s stock after purchasing an additional 417 shares during the period. Hedeker Wealth LLC’s holdings in Thermo Fisher Scientific were worth $3,919,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Eagle Ridge Investment Management grew its position in Thermo Fisher Scientific by 2.4% during the fourth quarter. Eagle Ridge Investment Management now owns 1,460 shares of the medical research company’s stock valued at $760,000 after buying an additional 34 shares during the period. GHP Investment Advisors Inc. grew its position in Thermo Fisher Scientific by 5.4% during the fourth quarter. GHP Investment Advisors Inc. now owns 6,287 shares of the medical research company’s stock valued at $3,271,000 after buying an additional 323 shares during the period. Oakworth Capital Inc. boosted its position in Thermo Fisher Scientific by 9.3% during the fourth quarter. Oakworth Capital Inc. now owns 3,093 shares of the medical research company’s stock worth $1,609,000 after purchasing an additional 262 shares during the period. YANKCOM Partnership bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $398,000. Finally, Bleakley Financial Group LLC boosted its position in Thermo Fisher Scientific by 7.3% during the fourth quarter. Bleakley Financial Group LLC now owns 11,868 shares of the medical research company’s stock worth $6,174,000 after purchasing an additional 812 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TMO shares. Citigroup increased their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. Redburn Atlantic began coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 target price for the company. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $658.00.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock valued at $11,231,699 over the last three months. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 1.8 %

TMO stock opened at $571.75 on Friday. The company has a market capitalization of $218.70 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company’s 50 day moving average price is $545.51 and its two-hundred day moving average price is $571.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.